These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 24681846)

  • 1. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
    Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
    Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
    Smith HA; Cronk RJ; Lang JM; McNeel DG
    Cancer Res; 2011 Nov; 71(21):6785-95. PubMed ID: 21880588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
    Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
    Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
    Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
    Smith HA; McNeel DG
    J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
    Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
    Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
    Held G; Neumann F; Sturm C; Kaestner L; Dauth N; de Bruijn DR; Renner C; Lipp P; Pfreundschuh M
    Int J Cancer; 2008 Oct; 123(8):1841-7. PubMed ID: 18688854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer.
    Zhang B; Ren Z; Zhao J; Zhu Y; Huang B; Xiao C; Zhang Y; Deng J; Mao L; Tang L; Lan D; Gao L; Zhang H; Chen G; Luo OJ
    Theranostics; 2023; 13(13):4449-4468. PubMed ID: 37649599
    [No Abstract]   [Full Text] [Related]  

  • 17. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
    Robbins PF; Li YF; El-Gamil M; Zhao Y; Wargo JA; Zheng Z; Xu H; Morgan RA; Feldman SA; Johnson LA; Bennett AD; Dunn SM; Mahon TM; Jakobsen BK; Rosenberg SA
    J Immunol; 2008 May; 180(9):6116-31. PubMed ID: 18424733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
    Neumann F; Wagner C; Stevanovic S; Kubuschok B; Schormann C; Mischo A; Ertan K; Schmidt W; Pfreundschuh M
    Int J Cancer; 2004 Nov; 112(4):661-8. PubMed ID: 15382048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.